Methods of treating cancer using lsd1 inhibitors in combination with immunotherapy
US-2024018242-A1 · Jan 18, 2024 · US
US11008552B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11008552-B2 |
| Application number | US-201916524382-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 29, 2019 |
| Priority date | May 24, 2019 |
| Publication date | May 18, 2021 |
| Grant date | May 18, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides a multicopper oxidase mutant with improved salt tolerance. Threonine at site 317 of wild-type multicopper oxidase WT was mutated to asparagine, leucine at site 386 was mutated to tyrosine, and serine at site 427 was mutated to glutamic acid by site-directed mutagenesis to obtain a mutant T317N-L386Y-S427E. Compared with WT, the tolerance of T317N-L386Y-S427E to 6%, 9%, 12%, 15% and 18% NaCl (W/V) is improved.
Opening claim text (preview).
What is claimed is: 1. A multicopper oxidase mutant, wherein: (a) the multicopper oxidase mutant comprises the amino acid sequence SEQ ID NO:1, or (b) the multicopper oxidase mutant comprises the amino acid sequence SEQ ID NO:1 with residue number 110 mutated to glutamic acid (A110E), and wherein the multicopper oxidase mutant possesses oxidase enzymatic activity. 2. A method for producing a multicopper oxidase mutant comprising: inoculating a genetically engineered bacterium transformed with a gene encoding a multicopper oxidase mutant of claim 1 into a medium; inducing the genetically engineered bacterium to express the gene; collecting the genetically engineered bacterium; disrupting the genetically engineered bacterium; and purifying the multicopper oxidase mutant from the disrupted genetically engineered bacterium. 3. The method according to claim 2 , which further comprises: adding the purified multicopper oxidase mutant to a food, thereby removing biogenic amines in the food by degradation. 4. The method according to claim 3 , wherein the food comprises soy sauce. 5. The method according to claim 3 , wherein the biogenic amine comprises at least one of tryptamine, phenethylamine, putrescine, cadaverine, histamine, tyramine, spermine and spermidine.
using enzymes · CPC title
Ferroxidase (1.16.3.1), i.e. ceruloplasmin · CPC title
Genes encoding for enzymes or proenzymes · CPC title
L-ascorbate oxidase (1.10.3.3) · CPC title
Laccase (1.10.3.2) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.